Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones increasing by approximately 350 points on Wednesday [1] Company Performance - Progress Software Corp reported fourth-quarter adjusted EPS of $1.51, surpassing the Street estimate of $1.31, and quarterly revenue of $252.67 million, slightly below the consensus estimate of $252.86 million [2] - Progress Software shares surged by 20.5% to $46.50 following the earnings report and positive first-quarter guidance [2] Other Notable Stock Movements - Rambus Inc saw a gain of 15.1%, reaching $126.67 [3] - ServisFirst Bancshares Inc increased by 13.3% to $86.45 after reporting better-than-expected fourth-quarter earnings [3] - Lucid Group Inc rose by 12.9% to $10.97 [3] - Red Cat Holdings Inc jumped 11.4% to $16.05 [3] - American Resources Corp surged 11% to $3.88 [3] - Zura Bio Ltd increased by 10.5% to $5.54, with a new CEO appointed [3] - SES AI Corp gained 10.5% to $2.42 [3] - Lexicon Pharmaceuticals Inc shares rose 10.3% to $1.44 after a successful FDA meeting for Pilavapadin [3] - Comstock Resources Inc increased by 9.8% to $24.49 [3] - Tronox Holdings PLC surged 9.5% to $6.06, with an analyst maintaining a Buy rating and raising the price target [3] - Teledyne Technologies Inc gained 9.2% to $618.47 after reporting better-than-expected quarterly results [3] - Intel Corp increased by 9.1% to $52.97 [3] - Arm Holdings PLC surged 9% to $116.81 after an upgrade from Neutral to Positive [3] - Nuscale Power Corp gained 8.1% to $20.50 [3] - Quantumscape Corp increased by 8% to $11.05 [3] - Moderna Inc rose 6.4% to $45.76, sharing positive data from a study on mRNA-based therapy [3]

Company Performance - Ultragenyx Pharmaceutical Inc. shares fell 42% to $19.84 following the announcement of Phase 3 study results for setrusumab (UX143) in Osteogenesis Imperfecta (OI) [1] - Mereo BioPharma Group plc shares dropped 90% to $0.23 after its Phase 3 studies for setrusumab did not achieve statistical significance against primary endpoints [5] Market Movements - Republic Power Group Ltd surged 163% to $0.69 [5] - Brand Engagement Network Inc jumped 84.3% to $2.21 after entering a Vendor Services Project Agreement [5] - DigitalBridge Group Inc rose 9.9% to $15.30 following the announcement of its acquisition by SoftBank Group for approximately $4.0 billion [5] Precious Metals Sector - Hycroft Mining Holding Corporation was down 14% to $21.61 as precious metal stocks traded lower due to a retreat in commodity prices [6] - Silver prices pulled back after reaching an all-time high, impacting related stocks [6]

Group 1 - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points on Monday [1] - DigitalBridge Group Inc announced its acquisition by SoftBank Group for an enterprise value of approximately $4.0 billion, resulting in a 9.9% increase in its shares to $15.30 [1] Group 2 - Eightco Holdings Inc shares surged 29.1% to $2.15 following the announcement of a share buyback program for up to $125 million [2] - Palisade Bio Inc saw an 18.6% increase to $2.55 after Piper Sandler initiated coverage with an Overweight rating and a price target of $25 [2] - Regencell Bioscience Holdings Ltd gained 16.3% to $24.60 [2] - Praxis Precision Medicines Inc surged 13% to $304.00 after receiving Breakthrough Therapy Designation from the FDA for ulixacaltamide [2] - Zura Bio Ltd increased by 13% to $5.26 [2] - Precigen Inc rose 8.6% to $4.52 [2] - Autolus Therapeutics PLC jumped 7.8% to $1.80, with Needham analyst raising the price target from $10 to $11 [2] - LightPath Technologies Inc gained 6.6% to $9.62 [2] - NGL Energy Partners LP surged 6.3% to $9.98 [2] - Six Flags Entertainment Corp increased by 5% to $15.64 [2]

Core Insights - Zura Bio Limited (NASDAQ:ZURA) has shown strong performance over the past three months and is identified as one of the 12 hot penny stocks to invest in currently [1] - Guggenheim has reiterated a "Buy" rating for Zura Bio with a price target of $15, reflecting a bullish outlook amid the progress of the tibulizumab Phase 2 clinical trial [2] Financial Performance - For Q3 2025, Zura Bio reported $139 million in cash, which is expected to fund operations until 2027 [3] - The company experienced an increase in R&D expenses to $11.9 million due to the tibulizumab Phase 2 clinical trial, while G&A expenses decreased to $7.6 million [3] - The net loss for the quarter was $20 million, or $0.21 per share, an improvement from the previous year's loss of $22.9 million, or $0.26 per share [3] Clinical Development - Zura Bio is advancing two Phase 2 studies for tibulizumab: TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis [4] - TibuSHIELD is on track to deliver topline data in Q3 2026, while TibuSURE's data is anticipated in Q4 2026 [4] - Management is focused on patient enrollment and addressing competitive trial recruitment dynamics [4] Company Overview - Zura Bio Limited is a clinical-stage immunology company that develops dual-pathway antibodies targeting autoimmune and inflammatory diseases [5]

Core Insights - Biotech stocks experienced significant gains in after-hours trading, with Inhibrx Biosciences leading the surge due to positive trial results [1][2] Company Summaries - **Inhibrx Biosciences (INBX)**: Shares surged over 81% to $51.52 following positive topline results from the ChonDRAgon study, which evaluated ozekibart as a monotherapy for advanced chondrosarcoma. The company also reported progress on expansion cohorts for colorectal cancer and Ewing sarcoma [2] - **Femasys Inc. (FEMY)**: Stock increased by more than 18% to $0.7227 after launching a post-market surveillance clinical study for its FemBloc Permanent Birth Control, complying with EU Medical Device Regulation [3] - **Cingulate Inc. (CING)**: Shares rose over 6% to $3.80 after announcing that data from its ADHD candidate CTx-1301 was selected for presentation at the AACAP Annual Meeting, highlighting its potential in ADHD treatment [4] - **Community Health Systems, Inc. (CYH)**: Stock increased over 4% to $3.41 following positive Q3 results [5] - **Reviva Pharmaceuticals Holdings Inc. (RVPH)**: Shares climbed over 10% to $0.6295 in after-hours trading [6] - **Ascendis Pharma A/S (ASND)**: Stock gained more than 4%, reaching $210.68 post-market [6] - **ADC Therapeutics SA (ADCT)**: Shares rose over 5% to $4.2887 in after-hours trading [6] - **Zura Bio Limited (ZURA)**: Stock increased more than 5% to $3.55 post-market [6] - **Foghorn Therapeutics Inc. (FHTX)**: Shares gained more than 5%, closing at $4.11 after hours [6]

Core Insights - 2026 is anticipated to be a crucial year for Zura Bio Ltd. (ZURA) as key data readouts for its lead investigational drug, Tibulizumab, are expected to significantly impact the company's strategic direction and market position [1] Company Overview - Zura Bio is a clinical-stage, multi-asset immunology company focused on developing treatments for immune-mediated diseases with unmet medical needs [1] - The lead product candidate, Tibulizumab, is a potential first-in-class dual-pathway biologic targeting cytokines IL-17A and BAFF [1] Clinical Trials - Tibulizumab is currently being evaluated in two global phase 2 studies: TibuSHIELD and TibuSURE [2][6] - TibuSHIELD is assessing Tibulizumab in adults with moderate to severe Hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting approximately 1% of the global population [3][5] - The TibuSHIELD trial, initiated in May 2025, aims to enroll about 180 adults and includes a 16-week efficacy assessment followed by a 12-week safety follow-up [5] - Topline results from the TibuSHIELD trial are expected in Q3 2026 [6] - TibuSURE is evaluating Tibulizumab for systemic sclerosis (SSc), a rare autoimmune disease affecting around 300,000 individuals worldwide [7][8] - The TibuSURE study, initiated in December 2024, plans to enroll roughly 80 participants and includes a 24-week efficacy period [8] - Topline results from the TibuSURE study are anticipated in Q4 2026 [9] Pipeline and Financial Position - Zura Bio has two additional investigational drugs, Crebankitug and Torudokimab, which have completed phase 1/1b studies and are being evaluated for various autoimmune and inflammatory conditions [9] - As of June 30, 2025, Zura Bio had cash and cash equivalents of $154.5 million, projected to support operations until 2027 [10] - Zura Bio made its Nasdaq debut on March 21, 2023, under the ticker symbol "ZURA" following a merger with JATT Acquisition Corp [10] Stock Performance - Over the past year, ZURA's stock has traded between $0.97 and $5.07, closing at $4.17, reflecting a 6.10% increase [11]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - SciSparc Ltd. (SPRC) is up 41% at $6.32 - Wolfspeed, Inc. (WOLF) is up 22% at $26.50 - Innovation Beverage Group Limited (IBG) is up 14% at $3.60 - Genasys Inc. (GNSS) is up 12% at $2.52 - Tamboran Resources Corporation (TBN) is up 9% at $24.84 - Fitell Corporation (FTEL) is up 8% at $6.09 - Zura Bio Limited (ZURA) is up 8% at $3.25 - Phio Pharmaceuticals Corp. (PHIO) is up 8% at $2.60 - AVITA Medical, Inc. (RCEL) is up 7% at $5.77 - Next Technology Holding Inc. (NXTT) is up 5% at $24.00 [3] Premarket Losers - Applied DNA Sciences, Inc. (APDN) is down 26% at $3.87 - Epsium Enterprise Limited (EPSM) is down 23% at $18.79 - Artelo Biosciences, Inc. (ARTL) is down 21% at $4.60 - Boqii Holding Limited (BQ) is down 14% at $8.52 - Top KingWin Ltd (WAI) is down 13% at $4.02 - bioAffinity Technologies, Inc. (BIAF) is down 13% at $2.82 - Firefly Aerospace Inc. (FLY) is down 12% at $36.96 - JFB Construction Holdings (JFB) is down 12% at $11.14 - Akanda Corp. (AKAN) is down 9% at $4.31 - Energy Fuels Inc. (UUUU) is down 6% at $15.41 [4]

Core Insights - Merus NV's shares increased by 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition deal, which includes the addition of the breakthrough therapy Petosemtamab to Genmab's late-stage pipeline [1] Gainers - Steakholder Foods Ltd rose 92% to $8.32 after announcing an agreement to acquire Twine Solutions [4] - JFB Construction Holdings surged 77.4% to $12.15 following a $44 million private placement announcement [4] - Plus Therapeutics gained 24.3% to $0.77 after securing a national coverage agreement with UnitedHealthcare for its CNSide assay [4] - Avalo Therapeutics rose 24.1% to $13.40 after a previous decline of 6% [4] - Enanta Pharmaceuticals gained 22.7% to $9.69 ahead of presenting topline results from its Phase 2b study of Zelicapavir for RSV [4] - Canopy Growth Corp jumped 19.4% to $1.60 [4] - Zura Bio Ltd gained 18.3% to $2.85 after a 15% increase on Friday [4] - Tilray Brands surged 17.4% to $1.35, with first-quarter financial results to be announced on October 9 [4] - Larimar Therapeutics jumped 16.4% to $5.93, with an update on the Nomlabofusp program scheduled for September 2 [4] Losers - MoonLake Immunotherapeutics dipped 86.3% to $8.50 despite achieving statistically significant results in its Phase 3 VELA trials [4] - Maris Tech fell 37.3% to $2.62 after reporting a H1 loss of 30 cents per share [4] - Sunrise New Energy Co Ltd shares dipped 28.1% to $0.88 after a previous 10% gain [4] - Cycurion Inc declined 15.5% to $0.28 after a significant drop of over 30% on Friday [4] - bioAffinity Technologies dipped 14.4% to $4.53 after a 55% increase on Friday [4] - Youxin Technology Ltd fell 13.9% to $0.058 following a 1-for-80 reverse split announcement [4] - Top KingWin Ltd declined 12.8% to $4.07 after a previous 48% increase [4] - Cellectis SA fell 10.4% to $3.01 [4] - Quantum-Si Inc decreased 10.1% to $1.34 after filing for a mixed shelf of up to $300 million [4] - Penguin Solutions Inc fell 8.4% to $24.00 [4]